{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:49:55Z","timestamp":1786985395721,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bjid.2025.104526","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T03:19:44Z","timestamp":1744082384000},"page":"104526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tuberculosis parenteral therapeutic regimens for critical patients or non-functional intestinal tract: Brief review and proposal of protocol"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7035-6788","authenticated-orcid":false,"given":"Antonio Camargo","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia Teixeira","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-0076","authenticated-orcid":false,"given":"Mari\u00e2ngela Ribeiro","family":"Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2025.104526_bib0001","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva; 2023."},{"key":"10.1016\/j.bjid.2025.104526_bib0002","unstructured":"Minist\u00e9rio de Sa\u00fade, Secretaria De Vigil\u00e2ncia Sa\u00fade e Ambiente, Departamento de HIV\/Aids T, Hepatites Virais e Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis. Epidemiological Report \u2013 Tuberculosis 2024. Brazil; 2024."},{"key":"10.1016\/j.bjid.2025.104526_bib0003","volume":"11","author":"Roure","year":"2023"},{"key":"10.1016\/j.bjid.2025.104526_bib0004","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pulmoe.2022.01.016","article-title":"Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systemti3c review","volume":"28","author":"Galvin","year":"2022","journal-title":"Pulmonology"},{"issue":"1","key":"10.1016\/j.bjid.2025.104526_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/tmi.13511","article-title":"Tuberculosis in the intensive care unit: alternative treatment regimens and association with mortality","volume":"26","author":"Anton","year":"2021","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.bjid.2025.104526_bib0006","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12879-016-1644-6","article-title":"Six-month survival of critically ill patients with HIV-related disease and tuberculosis: a retrospective study","volume":"16","author":"Pecego","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2025.104526_bib0007","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jcma.2018.02.003","article-title":"Contributing factors to mortality rates of pulmonary tuberculosis in intensive care units","volume":"81","author":"Tatar","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.bjid.2025.104526_bib0008","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jcrc.2018.03.015","article-title":"The critically ill patient with tuberculosis in intensive care: clinical presentations, management and infection control","volume":"45","author":"Otu","year":"2018","journal-title":"J Crit Care"},{"key":"10.1016\/j.bjid.2025.104526_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/cc12760","article-title":"Clinical review: tuberculosis on the intensive care unit","volume":"17","author":"Hagan","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.bjid.2025.104526_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12879-019-3751-7","article-title":"APACHE-II score for anti-tuberculosis tolerance in critically ill patients: a retrospective study","volume":"19","author":"Qiu","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2025.104526_bib0011","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7196\/SAMJ.6344","article-title":"The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care","volume":"103","author":"Koegelenberg","year":"2013","journal-title":"S Afr Med J"},{"key":"10.1016\/j.bjid.2025.104526_bib0012","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijid.2022.11.033","article-title":"The impact of enteral feeding and therapeu3c monitoring of rifampicin with dose escalation in critically ill patients with tuberculosis","volume":"126","author":"Perumal","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.bjid.2025.104526_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012163","article-title":"Six-month therapy for abdominal tuberculosis","volume":"11","author":"Jullien","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bjid.2025.104526_bib0014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2149\/tmh.2015-09","article-title":"Management of severe gastrointestinal tuberculosis with injectable anti-tuberculous drugs","volume":"43","author":"Goldani","year":"2015","journal-title":"Trop Med Health"},{"key":"10.1016\/j.bjid.2025.104526_bib0015","unstructured":"World Health Organization. Target Regimen Profiles For Tuberculosis treatment, 2023 Update. Geneva; 2023."},{"key":"10.1016\/j.bjid.2025.104526_bib0016","unstructured":"World Health Organization, Expert committee members and temporary advisors. 23rd expert committee on selection and use of essential medicines. 2021. Available at: https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/23rd-expert-committee [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0017","unstructured":"World Health Organization. Expert review: rifampicin IV. 2021 Expert commiree on selection and use of essential medicines. 2021. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/2021-eml-expert-committee\/expert-reviews\/f11_rifampiciniv_rev1.pdf?sfvrsn=72a8378_8 [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0018","unstructured":"World Health Organization. Expert review: isoniazid IV. 2021 Expert commiree on selection and use of essential medicines. 2021. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/2021-eml-expert-committee\/expert-reviews\/f9_isoniazidiv_rev1.pdf?sfvrsn=d52e4277_8 [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0019","unstructured":"World Health Organization. Expert review: ethambutol IV. 2021 Expert commiree on selection and use of essential medicines. 2021. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/2021-eml-expert-committee\/expert-reviews\/f7_ethambutol_rev1.pdf?sfvrsn=a9e3661c_8 [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0020","unstructured":"World Health Organization. Application for new formulations\/strengths of existing listed medicines: rifampicin IV. 2021. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/2021-eml-expert-committee\/applications-for-new-formulations-strengths-of-existing-listed-medicines\/f.11_rifampicin-iv.pdf?sfvrsn=f79277da_4 [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0021","unstructured":"World Health Organization. Application for new formulations\/strengths of existing listed medicines: isoniazid IV. 2021. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/2021-eml-expert-committee\/applications-for-new-formulations-strengths-of-existing-listed-medicines\/f.9_isoniazid-iv.pdf?sfvrsn=60d1bba_4 [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0022","unstructured":"World Health Organization. Application for new formulations\/strengths of exising listed medicines: ethambutol IV. 2021. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/2021-eml-expert-committee\/applications-for-new-formulations-strengths-of-existing-listed-medicines\/f.7_ethambutol-iv.pdf?sfvrsn=b858b57e_4 [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2025.01.023","article-title":"Revolutionizing tuberculosis treatment: breakthroughs, challenges, and hope on the horizon","author":"Kufa","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bjid.2025.104526_bib0025","unstructured":"Shanghai Jiatan Pharmatech Co. L. NCT05824871 \u2012 A phase III study of oral Sudapyridine (WX-081) tablets in rifampicin-resistant pulmonary tuberculosis Patients (SURE-TB). 2024."},{"issue":"6","key":"10.1016\/j.bjid.2025.104526_bib0026","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/pharmaceutics16060818","article-title":"New oxazolidinones for tuberculosis: are novel treatments on the horizon?","volume":"16","author":"Chen","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bjid.2025.104526_bib0027","unstructured":"Assistance Publique H\u00f4pitaux de Paris. NCT05534750 \u2012 evaluation of the early bactericidal activity of Tedizolid and Linezolide against mycobacterium tuberculosis (TEDITUB) (TEDITUB). 2024."},{"key":"10.1016\/j.bjid.2025.104526_bib0028","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s13063-023-07354-5","volume":"24","author":"Dierig","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.bjid.2025.104526_bib0029","unstructured":"World Health Organization. Web Annexes. In: WHO Operational Handbook On Tuberculosis. Module 4: treatment \u2012 drug-resistant tuberculosis treatment, 2022 update. WHO Operational Handbook on Tuberculosis. 2022."},{"key":"10.1016\/j.bjid.2025.104526_bib0030","unstructured":"Minist\u00e9rio da Sa\u00fade., Secretaria De Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis. Manual de Recomenda\u00e7\u00f5es para o controle da tuberculose no Brasil. Minist\u00e9rio Da Sa\u00fade \u2012 Brasil. 2019."},{"key":"10.1016\/j.bjid.2025.104526_bib0031","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.arbres.2020.03.021","article-title":"Actualizaci\u00f3n de la normativa SEPAR \u00abdiagn\u00f3stico y tratamiento de la tuberculosis con resistencia a f\u00e1rmacos\u00bb","volume":"56","author":"Caminero","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.bjid.2025.104526_bib0032","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official american thoracic society\/Centers for disease control and prevention\/Infectious diseases society of america clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.bjid.2025.104526_bib0033","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030412","article-title":"The treatment effect of levofloxacin, moxifloxacin, and Ga3floxacin contained in the conventional therapy regimen for pulmonary tuberculosis: systematic review and network meta-analysis","volume":"101","author":"He","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bjid.2025.104526_bib0034","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2025.104526_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005650","article-title":"Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach","volume":"13","author":"Pienaar","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.bjid.2025.104526_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145066","article-title":"Effects of fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bjid.2025.104526_bib0037","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40264-018-0751-2","article-title":"Fluoroquinolones and cardiovascular risk: a Systematic review, Meta-analysis and network meta-analysis","volume":"42","author":"Gorelik","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.bjid.2025.104526_bib0038","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against mycobacterium tuberculosis: evaluation of In vitro and pharmacodynamic indices that best predict In vivo efficacy","volume":"51","author":"Shandil","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104526_bib0039","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1128\/AAC.49.8.3178-3181.2005","article-title":"Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance","volume":"49","author":"Gumbo","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104526_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119301","article-title":"Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs","volume":"274","author":"Chauhan","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.bjid.2025.104526_bib0041","unstructured":"Queensland Health. Guideline for the use of amikacin for drug-resistant tuberculosis and nontuberculous mycobacterial infections. 2020. Available at: https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0023\/1044743\/tb-guideline-amikacin-drug-resistant.pdf [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0042","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"16","author":"Cox","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.bjid.2025.104526_bib0043","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bjid.2025.104526_bib0044","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01489-18","article-title":"Evaluation of carbapenems for treatment of multi- and extensively drug-resistant mycobacterium tuberculosis","volume":"63","author":"van Rijn","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2025.104526_bib0045","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/08971900221100205","article-title":"Bioavailability of orally administered drugs in critically III patients","volume":"36","author":"Forsberg","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.bjid.2025.104526_bib0046","first-page":"219","article-title":"API TB Consensus Guidelines 2006: management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations","volume":"54","author":"Consensus Expert Commiree","year":"2006","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.bjid.2025.104526_bib0047","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02876-23","article-title":"In vitro \u2012 optimization of crushed drug-sensitive anti-tuberculosis medication when administered via a nasogastric tube","volume":"12","author":"Phogole","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.bjid.2025.104526_bib0048","article-title":"Sanford Guide for web","year":"2025","journal-title":"Guide"},{"key":"10.1016\/j.bjid.2025.104526_bib0049","article-title":"Johns Hopkins ABX Guide","year":"2025","journal-title":"Guide"},{"key":"10.1016\/j.bjid.2025.104526_bib0050","unstructured":"UpToDate. Drug Interactions program. 2025. Available at: https:\/\/www.uptodate.com\/drug-interactions\/?source=responsive_home#di-druglist [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0051","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3201\/eid2503.180852","article-title":"Collaborative group for Meta-analysis of paediatric individual patient data in MDR TB. Treatment outcomes in global systematic review and patient Meta-analysis of children with extensively drug-resistant tuberculosis","volume":"25","author":"Osman","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bjid.2025.104526_bib0052","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tube.2015.02.037","article-title":"Fluoroquinolones for the treatment of tuberculosis in children","volume":"95","author":"Thee","year":"2015","journal-title":"Tuberculosis"},{"key":"10.1016\/j.bjid.2025.104526_bib0053","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(16)30474-1","article-title":"Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis","volume":"17","author":"Jenkins","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2025.104526_bib0054","unstructured":"WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. 2022."},{"key":"10.1016\/j.bjid.2025.104526_bib0055","series-title":"WHO Consolidated Guidelines On Drug-Resistant Tuberculosis Treatment","year":"2019"},{"key":"10.1016\/j.bjid.2025.104526_bib0056","unstructured":"Prescribing information: Sirturo\u00ae. FDA. 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/204384s019lbl.pdf [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0057","unstructured":"World Health Organization. Use of bedaquiline in children and adolescents with multidrug and rifampicin resistant tuberculosis. Inform Note. 2023. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240074286 [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0058","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/bcp.13696","article-title":"Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children","volume":"84","author":"Svensson","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bjid.2025.104526_bib0059","unstructured":"World Health Organization. Use of delamanid in children and adolescents with multidrug and rifampicin resistant tuberculosis. Inform Note. 2023. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240074309 [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0060","unstructured":"European Commission. DELAMANID (Deltyba\u00ae) Community register of medicinal products: annex I \u2012 summary of product characteristics. 2024. Available at: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240226161549\/anx_161549_en.pdf [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0061","unstructured":"Pretomanid (Pretomanid Tablets). US Food and Drug Administration (FDA). 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212862s008lbl.pdf [accessed January 31, 2025]."},{"key":"10.1016\/j.bjid.2025.104526_bib0062","unstructured":"World Health Organization. Terizidone: summary of product characteristics. Terizidone. 2018. Available at: https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/whopar_files\/TB303part4v1.pdf [accessed January 31, 2025]."}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867025000297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867025000297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T22:20:46Z","timestamp":1754086846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867025000297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1413867025000297"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2025.104526","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberculosis parenteral therapeutic regimens for critical patients or non-functional intestinal tract: Brief review and proposal of protocol","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2025.104526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104526"}}